Cargando…
PET: other thoracic malignancies
The vast majority of esophageal cancers are fluorodeoxyglucose (FDG) avid; the primary use for positron emission tomography (PET) in patients with esophageal cancer is in the detection of distant metastases, because known distant metastatic disease precludes surgical resection. High standardized upt...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
e-MED
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805061/ https://www.ncbi.nlm.nih.gov/pubmed/17114082 http://dx.doi.org/10.1102/1470-7330.2006.9015 |
_version_ | 1782132466348195840 |
---|---|
author | Quint, Leslie E |
author_facet | Quint, Leslie E |
author_sort | Quint, Leslie E |
collection | PubMed |
description | The vast majority of esophageal cancers are fluorodeoxyglucose (FDG) avid; the primary use for positron emission tomography (PET) in patients with esophageal cancer is in the detection of distant metastases, because known distant metastatic disease precludes surgical resection. High standardized uptake values (SUVs) may be predictive of poor prognosis. PET findings may be used to assess therapy response and evaluate for esophageal tumor recurrence after treatment. PET findings may be non-specific in different types of thymic lesions, although thymic carcinomas tend to be extremely FDG avid. PET can be helpful in detecting distant spread from invasive thymomas and thymic carcinomas. Similarly, PET may be used to assess the extent of disease in patients with malignant pleural mesothelioma, thereby facilitating optimal therapy approaches. |
format | Text |
id | pubmed-1805061 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | e-MED |
record_format | MEDLINE/PubMed |
spelling | pubmed-18050612008-10-31 PET: other thoracic malignancies Quint, Leslie E Cancer Imaging Article The vast majority of esophageal cancers are fluorodeoxyglucose (FDG) avid; the primary use for positron emission tomography (PET) in patients with esophageal cancer is in the detection of distant metastases, because known distant metastatic disease precludes surgical resection. High standardized uptake values (SUVs) may be predictive of poor prognosis. PET findings may be used to assess therapy response and evaluate for esophageal tumor recurrence after treatment. PET findings may be non-specific in different types of thymic lesions, although thymic carcinomas tend to be extremely FDG avid. PET can be helpful in detecting distant spread from invasive thymomas and thymic carcinomas. Similarly, PET may be used to assess the extent of disease in patients with malignant pleural mesothelioma, thereby facilitating optimal therapy approaches. e-MED 2006-10-31 /pmc/articles/PMC1805061/ /pubmed/17114082 http://dx.doi.org/10.1102/1470-7330.2006.9015 Text en Copyright © 2006 International Cancer Imaging Society |
spellingShingle | Article Quint, Leslie E PET: other thoracic malignancies |
title | PET: other thoracic malignancies |
title_full | PET: other thoracic malignancies |
title_fullStr | PET: other thoracic malignancies |
title_full_unstemmed | PET: other thoracic malignancies |
title_short | PET: other thoracic malignancies |
title_sort | pet: other thoracic malignancies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805061/ https://www.ncbi.nlm.nih.gov/pubmed/17114082 http://dx.doi.org/10.1102/1470-7330.2006.9015 |
work_keys_str_mv | AT quintlesliee petotherthoracicmalignancies |